Pathogenesis of diffuse large B cell lymphoma

International Journal of Hematology

Volumn 92, Issue 2, 2010, Pages 219-230

  Chan, Wing C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diffuse large B cell lymphoma; Oncogenic pathways; Pathogenesis

Indexed keywords

B LYMPHOCYTE RECEPTOR; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MICRORNA; PROTEIN BCL 2; PROTEIN P53; STAT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5;

APOPTOSIS; B LYMPHOCYTE; CELL MATURATION; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICRORNAS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 77956933850     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0602-0     Document Type: Review

References (84)

1. Swerdlow SH, Campo E. WHO classification: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
2. J Iqbal Z Liu, et al. 2009 Gene expression profiling in lymphoma diagnosis and management Best Pract Res Clin Haematol 22 2 191 210 10.1016/j.beha.2009.05.001 19698928 1:CAS:528:DC%2BD1MXhtVegs7bM
3. AS Ishkanian CA Malloff, et al. 2004 A tiling resolution DNA microarray with complete coverage of the human genome Nat Genet 36 3 299 303 10.1038/ng1307 14981516 1:CAS:528:DC%2BD2cXhsFOns7k%3D (Pubitemid 38282757)
4. S Bea A Zettl, et al. 2005 Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction Blood 106 9 3183 3190 10.1182/blood-2005-04-1399 16046532 1:CAS:528:DC%2BD2MXht1Wntr3E (Pubitemid 41565917)
5. G Lenz GW Wright, et al. 2008 Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci USA 105 36 13520 13525 10.1073/pnas.0804295105 18765795
6. ER Mardis RK Wilson 2009 Cancer genome sequencing: a review Hum Mol Genet 18 R2 R163 R168 10.1093/hmg/ddp396 19808792 1:CAS:528:DC%2BD1MXhtlCqu7nM
7. J Shendure H Ji 2008 Next-generation DNA sequencing Nat Biotechnol 26 10 1135 1145 10.1038/nbt1486 18846087 1:CAS:528:DC%2BD1cXht1aisrzK
8. DP Bartel 2009 MicroRNAs: target recognition and regulatory functions Cell 136 2 215 233 10.1016/j.cell.2009.01.002 19167326 1:CAS:528: DC%2BD1MXhs1Kiuro%3D
9. PA Sharp 2009 The centrality of RNA Cell 136 4 577 580 10.1016/j.cell.2009.02.007 19239877 1:CAS:528:DC%2BD1MXkvFGksLo%3D
10. RA Shivdasani 2006 MicroRNAs: regulators of gene expression and cell differentiation Blood 108 12 3646 3653 10.1182/blood-2006-01-030015 16882713 1:CAS:528:DC%2BD28Xht1Kgs77K (Pubitemid 44864540)
11. PS Eis W Tam, et al. 2005 Accumulation of miR-155 and BIC RNA in human B cell lymphomas Proc Natl Acad Sci USA 102 10 3627 3632 10.1073/pnas.0500613102 15738415 1:CAS:528:DC%2BD2MXisVOgsL8%3D (Pubitemid 40354662)
12. R Garzon S Volinia, et al. 2008 MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia Blood 111 6 3183 3189 10.1182/blood-2007-07-098749 18187662 1:CAS:528:DC%2BD1cXjvVamtbY%3D
13. R Malumbres KA Sarosiek, et al. 2009 Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas Blood 113 16 3754 3764 10.1182/blood-2008-10-184077 19047678 1:CAS:528:DC%2BD1MXlt1yjsLk%3D
14. J Zhang DD Jima, et al. 2009 Patterns of microRNA expression characterize stages of human B-cell differentiation Blood 113 19 4586 4594 10.1182/blood-2008-09-178186 19202128 1:CAS:528:DC%2BD1MXnvVyqtbc%3D
15. L Zhang J Huang, et al. 2006 microRNAs exhibit high frequency genomic alterations in human cancer Proc Natl Acad Sci USA 103 24 9136 9141 10.1073/pnas.0508889103 16754881 1:CAS:528:DC%2BD28XmsVWjsb8%3D (Pubitemid 43902545)
16. AA Alizadeh MB Eisen, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 6769 503 511 10.1038/35000501 10676951 1:CAS:528:DC%2BD3cXht1Shtrg%3D (Pubitemid 30082188)
17. A Rosenwald G Wright, et al. 2002 The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 25 1937 1947 10.1056/NEJMoa012914 12075054 (Pubitemid 34651353)
18. A Rosenwald G Wright, et al. 2003 Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J Exp Med 198 6 851 862 10.1084/jem.20031074 12975453 1:CAS:528:DC%2BD3sXnsV2ntL4%3D (Pubitemid 37152922)
19. KJ Savage S Monti, et al. 2003 The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma Blood 102 12 3871 3879 10.1182/blood-2003-06-1841 12933571 1:CAS:528:DC%2BD3sXpsFamur0%3D (Pubitemid 37486965)
20. S Karnan H Tagawa, et al. 2004 Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization Genes Chromosomes Cancer 39 1 77 81 10.1002/gcc.10298 14603444 1:CAS:528:DC%2BD2cXpsVar (Pubitemid 37475255)
21. T Kobayashi M Yamaguchi, et al. 2003 Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas Cancer Res 63 1 60 66 12517778 1:CAS:528:DC%2BD3sXjvFKmtA%3D%3D
22. Niitsu, N., M. Okamoto, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010
23. M Yamaguchi N Nakamura, et al. 2008 De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients Haematologica 93 8 1195 1202 10.3324/haematol.12810 18556402
24. J Iqbal WG Sanger, et al. 2004 BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma Am J Pathol 165 1 159 166 15215171 1:CAS:528:DC%2BD2cXmtFygsbo%3D
25. J Iqbal TC Greiner, et al. 2007 Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma Leukemia 21 11 2332 2343 10.1038/sj.leu.2404856 17625604 1:CAS:528:DC%2BD2sXht1WgsbbK (Pubitemid 350011706)
26. VL Brandt DB Roth 2008 G.O.D.'s Holy Grail: discovery of the RAG proteins J Immunol 180 1 3 4 18096995 1:CAS:528:DC%2BD2sXhsVGjur%2FN
27. L Deriano TH Stracker, et al. 2009 Roles for NBS1 in alternative nonhomologous end-joining of V(D)J recombination intermediates Mol Cell 34 1 13 25 10.1016/j.molcel.2009.03.009 19362533 1:CAS:528:DC%2BD1MXls1Srs7Y%3D
28. GS Lee MB Neiditch, et al. 2004 RAG proteins shepherd double-strand breaks to a specific pathway, suppressing error-prone repair, but RAG nicking initiates homologous recombination Cell 117 2 171 184 10.1016/S0092-8674(04) 00301-0 15084256 1:CAS:528:DC%2BD2cXjsFyrurg%3D (Pubitemid 38496238)
29. AG Tsai MR Lieber 2010 Mechanisms of chromosomal rearrangement in the human genome BMC Genomics 11 Suppl 1 S1 10.1186/1471-2164-11-S1-S1 20158866 1:CAS:528:DC%2BC3cXit1entr4%3D
30. JU Peled FL Kuang, et al. 2008 The biochemistry of somatic hypermutation Annu Rev Immunol 26 481 511 10.1146/annurev.immunol.26.021607.090236 18304001 1:CAS:528:DC%2BD1cXltlWktrw%3D (Pubitemid 351600383)
31. G Cattoretti J Mandelbaum, et al. 2009 Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation Cancer Res 69 22 8686 8692 10.1158/0008-5472.CAN-09-1110 19903857 1:CAS:528:DC%2BD1MXhtl2rsbfK
32. L Pasqualucci P Neumeister, et al. 2001 Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas Nature 412 6844 341 346 10.1038/35085588 11460166 1:CAS:528:DC%2BD3MXlsFGjs7Y%3D (Pubitemid 32691848)
33. M Liu JL Duke, et al. 2008 Two levels of protection for the B cell genome during somatic hypermutation Nature 451 7180 841 845 10.1038/nature06547 18273020 1:CAS:528:DC%2BD1cXhvVyms78%3D (Pubitemid 351253166)
34. G Lenz I Nagel, et al. 2007 Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma J Exp Med 204 3 633 643 10.1084/jem.20062041 17353367 1:CAS:528:DC%2BD2sXjsVyqsrs%3D (Pubitemid 46457085)
35. LM Staudt S Dave 2005 The biology of human lymphoid malignancies revealed by gene expression profiling Adv Immunol 87 163 208 10.1016/S0065-2776(05) 87005-1 16102574 1:CAS:528:DC%2BD1cXhsVOru7o%3D (Pubitemid 41135900)
36. G Lenz G Wright, et al. 2008 Stromal gene signatures in large-B-cell lymphomas N Engl J Med 359 22 2313 2323 10.1056/NEJMoa0802885 19038878 1:CAS:528:DC%2BD1cXhsVehtbvF
37. TD Gilmore 1992 Role of rel family genes in normal and malignant lymphoid cell growth Cancer Surv 15 69 87 1451115 1:STN:280:DyaK3s%2Fot1Krsw%3D%3D
38. G Lenz RE Davis, et al. 2008 Oncogenic CARD11 mutations in human diffuse large B cell lymphoma Science 319 5870 1676 1679 10.1126/science.1153629 18323416 1:CAS:528:DC%2BD1cXjsVamtbg%3D (Pubitemid 351432507)
39. M Compagno WK Lim, et al. 2009 Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 459 7247 717 721 10.1038/nature07968 19412164 1:CAS:528:DC%2BD1MXltlSrsLs%3D
40. K Honma S Tsuzuki, et al. 2009 TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas Blood 114 12 2467 2475 10.1182/blood-2008-12-194852 19608751 1:CAS:528:DC%2BD1MXht1Wktr3M
41. S Hailfinger G Lenz, et al. 2009 Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma Proc Natl Acad Sci USA 106 47 19946 19951 19897720 1:CAS:528:DC%2BD1MXhsFGjtL3F
42. K Dunleavy S Pittaluga, et al. 2009 Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 113 24 6069 6076 10.1182/blood-2009-01-199679 19380866 1:CAS:528:DC%2BD1MXnslSmurs%3D
43. MP Butler S Iida, et al. 2002 Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin's lymphoma Cancer Res 62 14 4089 4094 12124346 1:CAS:528:DC%2BD38XlsV2lsbk%3D
44. U Klein R Dalla-Favera 2008 Germinal centres: role in B-cell physiology and malignancy Nat Rev Immunol 8 1 22 33 10.1038/nri2217 18097447 1:CAS:528:DC%2BD2sXhsVKrsLnI
45. K Basso M Saito, et al. 2010 Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells Blood 115 5 975 984 10.1182/blood-2009-06-227017 19965633 1:CAS:528:DC%2BC3cXhvFOitrY%3D
46. SM Ranuncolo L Wang, et al. 2008 BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner J Biol Chem 283 33 22565 22572 10.1074/jbc.M803490200 18524763 1:CAS:528:DC%2BD1cXpsVKmsLk%3D
47. L Pasqualucci A Migliazza, et al. 2003 Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma Blood 101 8 2914 2923 10.1182/blood-2002-11-3387 12515714 1:CAS:528:DC%2BD3sXjtFCqsbw%3D (Pubitemid 36857975)
48. M Saito J Gao, et al. 2007 A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma Cancer Cell 12 3 280 292 10.1016/j.ccr.2007.08.011 17785208 1:CAS:528:DC%2BD2sXhtVKqsbrO (Pubitemid 47333420)
49. G Cattoretti L Pasqualucci, et al. 2005 Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice Cancer Cell 7 5 445 455 10.1016/j.ccr.2005.03.037 15894265 1:CAS:528: DC%2BD2MXkslyitLw%3D (Pubitemid 40719128)
50. LC Cerchietti EC Lopes, et al. 2009 A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas Nat Med 15 12 1369 1376 10.1038/nm.2059 19966776 1:CAS:528: DC%2BD1MXhsFWksb3N
51. JM Polo T Dell'Oso, et al. 2004 Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells Nat Med 10 12 1329 1335 10.1038/nm1134 15531890 1:CAS:528:DC%2BD2cXhtVCisbfJ (Pubitemid 40022714)
52. G Martins K Calame 2008 Regulation and functions of Blimp-1 in T and B lymphocytes Annu Rev Immunol 26 133 169 10.1146/annurev.immunol.26.021607.090241 18370921 1:CAS:528:DC%2BD1cXltlWksb8%3D (Pubitemid 351600373)
53. L Pasqualucci M Compagno, et al. 2006 Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma J Exp Med 203 2 311 317 10.1084/jem.20052204 16492805 1:CAS:528:DC%2BD28XhslCltro%3D (Pubitemid 43290840)
54. W Tam M Gomez, et al. 2006 Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas Blood 107 10 4090 4100 10.1182/blood-2005-09-3778 16424392 1:CAS:528:DC%2BD28XkvFWgsrc%3D (Pubitemid 43726818)
55. LT Lam G Wright, et al. 2008 Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma Blood 111 7 3701 3713 10.1182/blood-2007-09-111948 18160665 1:CAS:528:DC%2BD1cXktlWmtrw%3D
56. I Melzner AJ Bucur, et al. 2005 Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line Blood 105 6 2535 2542 10.1182/blood-2004-09-3701 15572583 1:CAS:528:DC%2BD2MXisFSktbY%3D (Pubitemid 40387056)
57. C Mestre F Rubio-Moscardo, et al. 2005 Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays Leukemia 19 6 1082 1084 10.1038/sj.leu.2403741 15815722 1:CAS:528:DC%2BD2MXktl2rtLc%3D (Pubitemid 40862024)
58. S Ilangumaran R Rottapel 2003 Regulation of cytokine receptor signaling by SOCS1 Immunol Rev 192 196 211 10.1034/j.1600-065X.2003.00020.x 12670405 1:CAS:528:DC%2BD3sXjsVOntLw%3D (Pubitemid 36613333)
59. O Ritz C Guiter, et al. 2009 Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma Blood 114 6 1236 1242 10.1182/blood-2009-03-209759 19423726 1:CAS:528:DC%2BD1MXhtVSgsbfE
60. S Shi HC Calhoun, et al. 2006 JAK signaling globally counteracts heterochromatic gene silencing Nat Genet 38 9 1071 1076 10.1038/ng1860 16892059 1:CAS:528:DC%2BD28XovVWjtrw%3D (Pubitemid 44325935)
61. L Chen S Monti, et al. 2008 SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Blood 111 4 2230 2237 10.1182/blood-2007-07-100115 18006696 1:CAS:528:DC%2BD1cXisVeit78%3D (Pubitemid 351451430)
62. M Gururajan CD Jennings, et al. 2006 Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma J Immunol 176 10 5715 5719 16670274 1:CAS:528:DC%2BD28XktVWgtr4%3D
63. RE Davis VN Ngo, et al. 2010 Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 7277 88 92 10.1038/nature08638 20054396 1:CAS:528:DC%2BC3cXhvFCitw%3D%3D
64. JW Friedberg J Sharman, et al. 2010 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 13 2578 2585 10.1182/blood-2009-08-236471 19965662 1:CAS:528:DC%2BC3cXksFOhs70%3D
65. KH Young K Leroy, et al. 2008 Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study Blood 112 8 3088 3098 10.1182/blood-2008-01-129783 18559976 1:CAS:528:DC%2BD1cXht1Omur7N
66. KH Young DD Weisenburger, et al. 2007 Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma Blood 110 13 4396 4405 10.1182/blood-2007-02-072082 17881637 1:CAS:528:DC%2BD1cXot1Wj (Pubitemid 351377806)
67. KJ Cheung DE Horsman, et al. 2009 The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target Br J Haematol 146 3 257 269 10.1111/j.1365-2141.2009. 07739.x 19500100 1:CAS:528:DC%2BD1MXhtValurrJ
68. R Honda H Yasuda 1999 Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 EMBO J 18 1 22 27 10.1093/emboj/18.1.22 9878046 1:CAS:528:DyaK1MXntVOguw%3D%3D (Pubitemid 29005019)
69. GA Calin C Sevignani, et al. 2004 Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers Proc Natl Acad Sci USA 101 9 2999 3004 10.1073/pnas.0307323101 14973191 1:CAS:528: DC%2BD2cXitlWhtr8%3D (Pubitemid 38327724)
70. L He JM Thomson, et al. 2005 A microRNA polycistron as a potential human oncogene Nature 435 7043 828 833 10.1038/nature03552 15944707 1:CAS:528:DC%2BD2MXkvVGgs70%3D (Pubitemid 40839734)
71. C Xiao L Srinivasan, et al. 2008 Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes Nat Immunol 9 4 405 414 10.1038/ni1575 18327259 1:CAS:528:DC%2BD1cXjtlGmsLo%3D (Pubitemid 351405110)
72. TC Chang D Yu, et al. 2008 Widespread microRNA repression by Myc contributes to tumorigenesis Nat Genet 40 1 43 50 10.1038/ng.2007.30 18066065 1:CAS:528:DC%2BD1cXhtVyqtQ%3D%3D
73. H Takahashi F Feuerhake, et al. 2006 FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes Clin Cancer Res 12 11 Pt 1 3265 3271 10.1158/1078-0432.CCR-06-0076 16740746 1:CAS:528:DC%2BD28XltFyju7c%3D
74. A Cimmino GA Calin, et al. 2005 miR-15 and miR-16 induce apoptosis by targeting BCL2 Proc Natl Acad Sci USA 102 39 13944 13949 10.1073/pnas.0506654102 16166262 1:CAS:528:DC%2BD2MXhtVOqsbjK (Pubitemid 41377683)
75. C Moller J Alfredsson, et al. 2005 Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim Blood 106 4 1330 1336 10.1182/blood-2004-12-4792 15855272 1:CAS:528:DC%2BD2MXosVejt74%3D (Pubitemid 41129597)
76. SS Dave K Fu, et al. 2006 Molecular diagnosis of Burkitt's lymphoma N Engl J Med 354 23 2431 2442 10.1056/NEJMoa055759 16760443 1:CAS:528: DC%2BD28XlsVaisro%3D (Pubitemid 43855046)
77. LM Rimsza RA Roberts, et al. 2006 Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions Blood 107 3 1101 1107 10.1182/blood-2005-04-1510 16239429 1:CAS:528:DC%2BD28Xht1Ont7Y%3D (Pubitemid 43156311)
78. RA Roberts G Wright, et al. 2006 Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival Blood 108 1 311 318 10.1182/blood-2005-11-4742 16543468 1:CAS:528:DC%2BD28XmsVOmu7s%3D (Pubitemid 43990644)
79. S Gross P Walden 2008 Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer Immunol Lett 116 1 7 14 10.1016/j.imlet.2007.11.012 18164076 1:CAS:528:DC%2BD1cXhtl2isrg%3D
80. TL Whiteside 2008 The tumor microenvironment and its role in promoting tumor growth Oncogene 27 45 5904 5912 10.1038/onc.2008.271 18836471 1:CAS:528:DC%2BD1cXhtF2msbbK
81. R Dolcetti M Boiocchi 1996 Cellular and molecular bases of B-cell clonal expansions Clin Exp Rheumatol 14 Suppl 14 S3 S13 8722194
82. JD Pound J Gordon 1997 Maintenance of human germinal center B cells in vitro Blood 89 3 919 928 9028323 1:CAS:528:DyaK2sXptVKmuw%3D%3D (Pubitemid 27121285)
83. M Wiesner C Zentz, et al. 2008 Conditional immortalization of human B cells by CD40 ligation PLoS One 3 1 e1464 10.1371/journal.pone.0001464 18213373 1:CAS:528:DC%2BD1cXhvFClt7k%3D (Pubitemid 351781190)
84. D Gratzinger S Zhao, et al. 2008 Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy Lab Invest 88 1 38 47 10.1038/labinvest. 3700697 17998899 1:CAS:528:DC%2BD1cXhtVyhug%3D%3D